T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Pfizer Inc(PFE)

Mar 28, 2007
The drug stocks in the US have been beat up. The problems they had have gotten somewhat better. Increased their dividend and are investing in more R&D. Buying back shares. Low multiple.
Photo of Norman LevineNorman LevineUnlock Rating
$25.18

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 22, 2007
Doesn't like many of the big pharmaceuticals. Has a great deal of revenue at risk with Lipitor coming off patent and they don't have a lot to replace it.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.79

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 13, 2007
(A Top Pick Dec 5/06. Up to .3%.) Still has lots of upside and it has a good yield. Have a lot of cash.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.94

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Mar 08, 2007
(A Top Pick Dec 21/06. Down 2.5%.) Sold their consumer business. There is so much value there. New management is cutting costs. 4.7% dividend. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.41

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 12, 2007
Pays a nice dividend. Have tons of cash through their normal cash generation as well as selling their consumers product division. Using some of it to increase dividends and some to buy back shares. 13 X earnings.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.22

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 01, 2007
This is a balance sheet story. They have a huge balance sheet that they can’t do anything with. Volatility in the stock price has fallen. New management wants to fire 10,000 people, etc. and it sounds like he wants to reduce the balance sheet. A restructuring story. 5% dividend. His current model price is $40, a 51% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.62

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 25, 2007
Drug companies have been struggling under generic competition as well as a difficult regulatory environment. Looks like compelling value here but would be more comfortable at $24.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$26.36

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 24, 2007
Hard one to play because it's in the drug space and there is a lot of litigation happening. From a trading perspective, this is a dangerous one to play.
Photo of John ManleyJohn Manley
No
Unlock Rating
$26.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 22, 2007
Big pharmaceutical pipelines product lines are getting squeezed and they have to cut costs. Relatively cheap, but the growth rate is not as good as it was.
Photo of John ZechnerJohn ZechnerUnlock Rating
$26.95

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 15, 2007
Like many of the pharmaceuticals, it is a company in transition. Won't go up aggressively, but it pays a decent yield. Historically, these companies have done well and they throw off a lot of free cash flow. New management is expected to cut costs and the company is buying back stock. Good balance sheet. Cheap.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.64

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 09, 2007
They have a great balance sheet and a yield over 4%. If you own, he would stick with it at this time.
Photo of Charles LannonCharles Lannon
No
Unlock Rating
$26.17

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 04, 2007
Had a number of one time issues that have been happening which has made it a bad investment for the last 5 years. Probably near its bottom now. Would consider it in the $21 area.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$26.38

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 03, 2007
If you want to stay in the pharmaceutical space, he would prefer Eli Lilly (LLY-N).
Photo of Steve MacMillanSteve MacMillan
No
Unlock Rating
$26.29

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 21, 2006
His model price is $39. That’s a 49% positive differential. Looking out 1 year with their earnings, it’s a 15% return, plus the dividend of 4.4% gives a 20% implied rate of return.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 18, 2006
Pulled a replacement for Lipitor because of poor tests. Wasn’t going to contribute until 2010. Stock dropped. Near its all time low. Pristine balance sheet. Oversold.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
Owned
Unlock Rating
$25.83

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 586 to 600 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like